Elaris

Description

Elaris develops next‑generation vaccines to prevent Clostridioides difficile infection. The company advances a dual‑mode vaccine designed to neutralize toxins and target bacterial colonization, focusing on vaccine development and technical/CMC activities to protect vulnerable populations.

Elaris is located in the Vienna ecosystem.

Related

• EveliqureEveliqure develops live attenuated and engineered bacterial vaccine candidates to prevent diarrhoeal diseases, including a first-generation…
• Bavarian NordicBavarian Nordic researches, develops, and manufactures life-saving vaccines, maintains product and pipeline materials, and operates process…
• MinervaXMinervaX is developing a prophylactic Group B Streptococcal (GBS) vaccine, AlpN GBS, that works as a clinical-stage immunization product…
• DebiopharmDebiopharm develops and manufactures pharmaceutical drugs and invests in digital health, focusing on oncology and bacterial infections and…
• BelynticBelyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to…
• AntabioAntabio develops antibacterial therapies for multidrug-resistant Gram-negative infections and advances Meropenem-Pilabactam, a…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• SURI BioTechSURI BioTech develops proprietary probiotic bacterial strains that demonstrate defined mechanisms of action to modulate intestinal…